# DAIICHI SANKYO CO LTD

Summary updated: 2026-10-02T09:05:37.515631Z
Canonical: https://finbar.com/research/companies/daiichi-sankyo-co

## Overview

Daiichi Sankyo Co., Ltd. is a global pharmaceutical company that discovers, develops, and delivers medicines. Its portfolio spans oncology, cardiovascular medicines, other pharmaceuticals, and vaccines, with antibody-drug conjugates among its defining oncology technologies. [1](https://www.daiichisankyo.com/about_us/mission-strength/what_we_do/)[2](https://www.daiichisankyo.com/products/) Its businesses and products serve markets across Japan, the Americas, Europe, and Asia and Oceania. [3](https://app.finbar.com/go?id=P134460900)[4](https://www.daiichisankyo.com/about_us/corporate_info/group/)

The company’s stated purpose is to contribute to the enrichment of quality of life around the world; its mission is to create innovative pharmaceuticals for diverse medical needs. [5](https://www.daiichisankyo.com/about_us/mission-strength/vision/) As of March 31, 2026, Daiichi Sankyo reported 20,171 Group employees and operations in 32 countries and regions. [6](https://www.daiichisankyo.com/about_us/) For the fiscal year ended March 31, 2026, revenue was ¥2,123.0 billion. [7](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Financial_Results_E.pdf)
[3](https://app.finbar.com/go?id=P134460900)[1](https://www.daiichisankyo.com/about_us/mission-strength/what_we_do/)[2](https://www.daiichisankyo.com/products/)[4](https://www.daiichisankyo.com/about_us/corporate_info/group/)[5](https://www.daiichisankyo.com/about_us/mission-strength/vision/)[6](https://www.daiichisankyo.com/about_us/)[7](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Financial_Results_E.pdf)

## Products & services

Daiichi Sankyo’s products include prescription medicines across oncology, cardiovascular disease, pain and other therapeutic areas, as well as vaccines. Named products include ENHERTU (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate (ADC); DATROWAY (datopotamab deruxtecan), a TROP2-directed ADC; LIXIANA (edoxaban), an anticoagulant; and TARLIGE (mirogabalin), a treatment for neuropathic pain. Approved uses and product availability vary by market. [2](https://www.daiichisankyo.com/products/) [8](https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2025/VR2025_EN_4_2.pdf)

Its DXd ADC platform combines a monoclonal antibody with a topoisomerase-I inhibitor payload derived from exatecan, using a cleavable linker. ENHERTU targets HER2, while DATROWAY targets TROP2. [9](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202602/20260204_E.pdf) Daiichi Sankyo also has product-related collaboration and supply responsibilities: ENHERTU is jointly developed and commercialized with AstraZeneca, with Daiichi Sankyo retaining rights in Japan; Daiichi Sankyo is responsible for manufacturing and supply of DATROWAY under its global collaboration. [10](https://www.daiichisankyo.com/media/press_release/detail/index_3199.html) [11](https://www.daiichisankyo.com/media/press_release/detail/index_3126.html)

ENHERTU generated ¥819.5 billion in FY2025, approximately 38.6% of consolidated revenue of ¥2,123.0 billion. In FY2026 Q1, ENHERTU revenue was ¥239.8 billion and DATROWAY revenue was ¥23.9 billion; both figures included milestone payments. [7](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Financial_Results_E.pdf) [12](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf)
[13](https://app.finbar.com/go?id=P134460942)[2](https://www.daiichisankyo.com/products/)[8](https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2025/VR2025_EN_4_2.pdf)[9](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202602/20260204_E.pdf)[10](https://www.daiichisankyo.com/media/press_release/detail/index_3199.html)[11](https://www.daiichisankyo.com/media/press_release/detail/index_3126.html)[7](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Financial_Results_E.pdf)[12](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf)

## Geographic presence

For the fiscal year ended March 31, 2026, Daiichi Sankyo reported revenue of ¥2,123.0 billion. By region, Japan accounted for ¥580.1 billion (27.3%), North America ¥749.4 billion (35.3%), Europe ¥497.4 billion (23.4%), and Other regions ¥296.2 billion (14.0%). “Other regions” is the company’s reported category. [14](https://www.daiichisankyo.com/investors/financial_highlights/)

The company reports 45 group companies across 32 countries and regions, with 13 research facilities in 3 countries or regions and 13 production locations in 6. Its overseas research institutes include locations in Boston, Munich, and San Diego. [6](https://www.daiichisankyo.com/about_us/)[15](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202510/20251002_E2.pdf)
[14](https://www.daiichisankyo.com/investors/financial_highlights/)[6](https://www.daiichisankyo.com/about_us/)[15](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202510/20251002_E2.pdf)

## Business segments

Daiichi Sankyo reports one operating segment: **pharmaceuticals**, encompassing its pharmaceutical business. It does not disclose separate operating-segment revenue contributions; on that basis, pharmaceuticals represents 100% of reported segment activity. The latest full-year figures are for FY2025, ended March 31, 2026. [16](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025_Amended_Consolidated_FS_and_Independent_Auditors_Report.pdf)

As a separate view—not an operating-segment breakdown—FY2025 sales by customer location were approximately 27.3% Japan, 35.3% North America, 23.4% Europe, and 14.0% other regions. [14](https://www.daiichisankyo.com/investors/financial_highlights/)
[16](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025_Amended_Consolidated_FS_and_Independent_Auditors_Report.pdf)[14](https://www.daiichisankyo.com/investors/financial_highlights/)

## Company history

Daiichi Sankyo traces its roots to two Japanese pharmaceutical companies. Sankyo Shoten was established in 1899, the year it launched Taka-Diastase; it later introduced Adrenalin in 1902. Daiichi’s predecessor, Arsemin Shokai, was founded in 1915 and became Daiichi Pharmaceutical Co., Ltd. in 1918. Sankyo began overseas expansion with a New York branch in 1918 and a Taipei branch in 1920. [17](https://www.daiichisankyo.com/about_us/mission-strength/history/sankyo/)[18](https://www.daiichisankyo.com/about_us/mission-strength/history/daiichi/)[19](https://www.daiichisankyo.com/our_stories/detail/index_4604.html)

The companies developed and marketed medicines internationally in the decades before their merger. Notable milestones included Daiichi’s launch of Cravit® (levofloxacin) in 1993 and Sankyo’s development of Mevalotin® and olmesartan. Sankyo and Daiichi Pharmaceutical established DAIICHI SANKYO COMPANY, LIMITED by stock transfer on September 28, 2005; the merged operating company began business on April 1, 2007. [18](https://www.daiichisankyo.com/about_us/mission-strength/history/daiichi/)[17](https://www.daiichisankyo.com/about_us/mission-strength/history/sankyo/)[20](https://www.daiichisankyo.com/media/press_release/detail/index_4071.html)[21](https://www.daiichisankyo.com/about_us/mission-strength/history/)

After the merger, Daiichi Sankyo expanded its biotechnology and oncology capabilities through acquisitions, including U3 Pharma in 2008 and Plexxikon in 2011. It also acquired a majority stake in Ranbaxy in 2008, but exited the investment after Sun Pharma’s merger with Ranbaxy was completed in 2015. In 2019, Daiichi Sankyo and AstraZeneca entered a global development and commercialization collaboration for trastuzumab deruxtecan, later marketed as ENHERTU; the medicine received accelerated approval in the United States that year. [22](https://www.daiichisankyo.com/media/press_release/detail/index_3949.html)[23](https://www.daiichisankyo.com/media/press_release/detail/index_3945.html)[24](https://www.daiichisankyo.com/media/press_release/detail/index_3788.html)[25](https://www.daiichisankyo.com/media/press_release/detail/index_3515.html)[10](https://www.daiichisankyo.com/media/press_release/detail/index_3199.html)[26](https://www.daiichisankyo.com/media/press_release/detail/index_3159.html)
[17](https://www.daiichisankyo.com/about_us/mission-strength/history/sankyo/)[18](https://www.daiichisankyo.com/about_us/mission-strength/history/daiichi/)[19](https://www.daiichisankyo.com/our_stories/detail/index_4604.html)[20](https://www.daiichisankyo.com/media/press_release/detail/index_4071.html)[21](https://www.daiichisankyo.com/about_us/mission-strength/history/)[22](https://www.daiichisankyo.com/media/press_release/detail/index_3949.html)[23](https://www.daiichisankyo.com/media/press_release/detail/index_3945.html)[24](https://www.daiichisankyo.com/media/press_release/detail/index_3788.html)[25](https://www.daiichisankyo.com/media/press_release/detail/index_3515.html)[10](https://www.daiichisankyo.com/media/press_release/detail/index_3199.html)[26](https://www.daiichisankyo.com/media/press_release/detail/index_3159.html)

## Sources

1. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/mission-strength/what_we_do/)
2. [www.daiichisankyo.com](https://www.daiichisankyo.com/products/)
3. [DAIICHI SANKYO CO LTD — Presentation (2025 Q 3), p6](https://app.finbar.com/go?id=P134460900)
4. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/corporate_info/group/)
5. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/mission-strength/vision/)
6. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/)
7. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025Q4_Financial_Results_E.pdf)
8. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/investors/library/annual_report/index/pdf/VR2025/VR2025_EN_4_2.pdf)
9. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202602/20260204_E.pdf)
10. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3199.html)
11. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3126.html)
12. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202607/20260731_E4.pdf)
13. [DAIICHI SANKYO CO LTD — Presentation (2025 Q 3), p10](https://app.finbar.com/go?id=P134460942)
14. [www.daiichisankyo.com](https://www.daiichisankyo.com/investors/financial_highlights/)
15. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/news/pressrelease/pdf/202510/20251002_E2.pdf)
16. [www.daiichisankyo.com](https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/FY2025_Amended_Consolidated_FS_and_Independent_Auditors_Report.pdf)
17. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/mission-strength/history/sankyo/)
18. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/mission-strength/history/daiichi/)
19. [www.daiichisankyo.com](https://www.daiichisankyo.com/our_stories/detail/index_4604.html)
20. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_4071.html)
21. [www.daiichisankyo.com](https://www.daiichisankyo.com/about_us/mission-strength/history/)
22. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3949.html)
23. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3945.html)
24. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3788.html)
25. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3515.html)
26. [www.daiichisankyo.com](https://www.daiichisankyo.com/media/press_release/detail/index_3159.html)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.